Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update

Reuters

11/28

Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update

Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and Voyager Acquisition Corp., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2586278100"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586278100\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586278100?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586278100","market":"fut","top_or_hot":-1,"title":"Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-28 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and <a href=\"https://laohu8.com/S/VACH\">Voyager Acquisition Corp</a>., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VACH","symbol_name":"Voyager Acquisition Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDLQZ3Kz:1","article_id":"2586278100","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586278100","pubTimestamp":1764331995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and Voyager Acquisition Corp., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VACH":"Voyager Acquisition Corp"},"translate_title":"Xlife Sciences AG在SEC文件更新后推进VERAXA Biotech纳斯达克上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VACH":0.9},"content_text":"Xlife Sciences AG Advances VERAXA Biotech NASDAQ Listing After SEC Filing Update\n    \n\n        Xlife Sciences AG provided an update on the planned combination between its portfolio company, VERAXA Biotech AG, and Voyager Acquisition Corp., a U.S.-listed special purpose acquisition company. VERAXA recently filed an amendment to its registration statement with the U.S. Securities and Exchange Commission following delays caused by a 43-day U.S. government shutdown. The extraordinary general meeting for VERAXA shareholders to approve the business combination is expected to be scheduled in December 2025. Xlife Sciences AG anticipates that VERAXA's listing on NASDAQ will be completed in the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xlife Sciences AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2237500_en), on November 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}